Evidence Library
Filter by drug, type, year, and open access.
Showing 1–5 of 5 results
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial — JAMA Psychiatry (2026)• Drug: semaglutide-wegovyPMID
- GLP-1 receptor agonists for atypical antipsychotic-related metabolic dysfunctions (systematic review) — Experimental and Therapeutic Medicine (2023)• Drug: semaglutide-wegovyOpen accessPMIDPMCID
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (2021)• Drug: semaglutide-wegovyDOI
- Liraglutide for Prediabetes/Obesity in Clozapine- or Olanzapine-Treated Schizophrenia Spectrum Disorder (RCT) — JAMA Psychiatry (2017)• Drug: semaglutide-wegovyOpen accessPMIDPMCID
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — New England Journal of Medicine (2016)• Drug: semaglutide-wegovyDOI